Madrigal Pharmaceuticals sees stock drop amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 06 Jan 26
Source: Coinmarketcap
Madrigal Pharmaceuticals Inc. experienced a price decline of 6.03%, hitting a 5-day low, while the broader market showed positive movement with the Nasdaq-100 up 0.57% and the S&P 500 up 0.28%.
This decline occurs despite Madrigal's strong sales performance, with $287.3 million in net sales reported for Q3 2024, indicating robust market demand for its product Rezdiffra. The company's growth potential remains strong, particularly as it is expected to enter blockbuster territory next year, highlighting its competitive position in the market.
The stock's movement reflects sector rotation, as investors may be reallocating their portfolios in response to broader market trends, despite Madrigal's solid fundamentals.
Analyst Views on MDGL
Wall Street analysts forecast MDGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 636.22 USD with a low forecast of 527.00 USD and a high forecast of 900.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 494.690
Low
527.00
Averages
636.22
High
900.00
Current: 494.690
Low
527.00
Averages
636.22
High
900.00
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
